ArticleFrontiers in oncology2026
Downstaging therapy of intermediate-stage hepatocellular carcinoma: microwave ablation vs. surgical resection.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Transarterial chemoembolization(TACE) is a potential downstaging therapeutic strategy for intermediate-stage hepatocellular carcinoma(HCC). However, therapeutic options following conversion therapy is still controversial. Purpose: This study aimed to compare the efficacy and safety of surgical resection(SR) and microwave ablation(MWA) following TACE based downstaging therapy for intermediate-stage HCC. Methods: From January 2008 to December 2021, a total of 2,125 consecutive patients with intermediate-stage HCC underwent initial TACE at seven hospitals were identified. Among them, 554 eligible HCC patients occurred objective response(OR) to TACE, who meet the tumor burden equivalence of early-stage disease. The propensity score matching(PSM) was applied to reduce selection bias. The overall survival(OS) and recurrence-free survival (RFS) were compared using the Kaplan-Meier method with the log-rank test. Independent risk factors for survival outcomes were identified through multivariable Cox analyses using forward stepwise regression. Results: After PSM 1:1, 152 patients in MWA group were matched with those in SR group. SR demonstrated comparable long-term survival outcomes (5-years OS rate, 85.3% vs 82.5% and 5-years RFS rate, 77.2% vs 75.0%) than MWA. Multivariate analyses showed that the factors that significantly affected the OS were Body Mass Index (hazard ratio[HR]:0.61;95% confidence interval [CI]: 0.37-0.82). Multivariate analyses showed that the interval between local-region treatment and TACE (HR:0.41; 95% CI: 0.24-0.67), HBV (HR: 0.32; 95% CI: 0.15-0.69) and systemic treatment (HR:0.44; 95% CI: 0.25-0.76) significantly affected the RFS. Conclusions: MWA might be acceptable as an alternative to SR in first-line TACE based downstaging therapeutic scheme for patients with intermediate-stage HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.